Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | GBA1 | P04062 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549776 | 0.95 | HRH4 (0.48) | HRH4HRH3CYP19A1GBA1L3MBTL1 | |
| SCHEMBL23613270 | 0.94 | HRH4 (0.49) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL19176415 | 0.94 | HRH4 (0.49) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL5021146 | 0.94 | HRH4 (0.49) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL3546672 | 0.92 | HRH4 (0.51) | HRH4HRH3CYP19A1GBA1L3MBTL1 | |
| SCHEMBL18789724 | 0.91 | GBA1 (0.54) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL3434883 | 0.90 | HRH4 (0.45) | HRH4HRH3CYP19A1GBA1L3MBTL1 | |
| SCHEMBL3434876 | 0.90 | HRH4 (0.42) | HRH4HRH3CYP19A1GBA1L3MBTL1 | |
| SCHEMBL10081200 | 0.90 | CYP19A1 (0.44) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL5020919 | 0.89 | GBA1 (0.56) | HRH4HRH3CYP19A1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20200308236-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200085908-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9957296-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | HRH4 3864/4885HRH3 3432/4885CYP19A1 3353/4885 |
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-20180193422-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885CYP19A1 3464/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885CYP19A1 2899/4885 |
| US-20200308236-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | HRH4 3426/4885HRH3 2932/4885CYP19A1 4873/4885 |
| US-20200085908-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | HRH4 4471/4885HRH3 4541/4885CYP19A1 939/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | HRH4 2639/4885HRH3 2900/4885CYP19A1 2105/4885 |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | HRH4 1954/4885HRH3 2166/4885CYP19A1 154/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | HRH4 1115/4885HRH3 912/4885CYP19A1 2898/4885 |
| US-10772934-B2 | Highly active polypeptides and methods of making and using the same | SCTR, GIPR, APLNR | HRH4 1644/4885HRH3 2078/4885CYP19A1 3464/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | HRH4 3022/4885HRH3 2281/4885CYP19A1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.